Literature DB >> 16227523

Natural history of Fabry disease in females in the Fabry Outcome Survey.

P B Deegan1, A F Baehner, M-A Barba Romero, D A Hughes, C Kampmann, M Beck.   

Abstract

BACKGROUND: Fabry disease is a rare X linked lysosomal storage disorder resulting from deficiency of alpha-galactosidase A activity. Although the severity of clinical features in male patients is well described, only recently have studies reported the high prevalence of disabling clinical features in heterozygous females. AIMS: This study sets out to examine the clinical features and natural history of Fabry disease in further detail in a large group of female patients.
METHODS: Data were obtained from 303 females enrolled in the Fabry Outcome Survey. Pain was assessed using the Brief Pain Inventory, and health related quality of life (HRQoL) was assessed using the European Quality of Life Questionnaire. A modified version of the Mainz Severity Score Index was also applied. Data on left ventricular mass (LVM) index, mean ventricular wall thickness, and glomerular filtration rate (GFR) were used to assess cardiac and renal involvement.
RESULTS: The most commonly reported clinical features in females were neurological (77%) and cardiac (59%). A history of renal involvement was recorded in 40% of cases. Neurological features were the earliest to develop (mean age: 16 years), whereas cardiac (mean age: 33.5 years) and renal (mean age: 37.3 years) features developed later. LVM index increased exponentially with age. In addition, age was negatively correlated with estimated GFR and HRQoL.
CONCLUSIONS: Females with Fabry disease report important age related clinical features and clinical investigation demonstrates evidence of disease progression. This study highlights the importance of careful and longitudinal assessment of female heterozygote patients with Fabry disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227523      PMCID: PMC2563231          DOI: 10.1136/jmg.2005.036327

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  24 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  Natural history of Fabry disease in affected males and obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 3.  EQ-5D: a measure of health status from the EuroQol Group.

Authors:  R Rabin; F de Charro
Journal:  Ann Med       Date:  2001-07       Impact factor: 4.709

4.  Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention.

Authors:  A H Miners; A Holmes; L Sherr; C Jenkinson; K D MacDermot
Journal:  Qual Life Res       Date:  2002-03       Impact factor: 4.147

5.  Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Authors:  C Whybra; C Kampmann; I Willers; J Davies; B Winchester; J Kriegsmann; K Brühl; A Gal; S Bunge; M Beck
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

6.  Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population.

Authors:  Robert Dobrovolny; Lenka Dvorakova; Jana Ledvinova; Sudheera Magage; Jan Bultas; Jean C Lubanda; Milan Elleder; Debora Karetova; Marketa Pavlikova; Martin Hrebicek
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

7.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

8.  Cardiac manifestations of Anderson-Fabry disease in heterozygous females.

Authors:  Christoph Kampmann; Frank Baehner; Catharina Whybra; Claudia Martin; Christiane M Wiethoff; Markus Ries; Andreas Gal; Michael Beck
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

9.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

Review 10.  Pain assessment: the advantages of using pain scales in lysosomal storage diseases.

Authors:  C S Cleeland
Journal:  Acta Paediatr Suppl       Date:  2002
View more
  80 in total

Review 1.  Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.

Authors:  Carla E M Hollak; Johannes M F G Aerts; Ségolène Aymé; Jeremy Manuel
Journal:  Orphanet J Rare Dis       Date:  2011-04-16       Impact factor: 4.123

2.  The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.

Authors:  A C Vedder; G E Linthorst; M J van Breemen; J E M Groener; F J Bemelman; A Strijland; M M A M Mannens; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2007-01-05       Impact factor: 4.982

3.  Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. In reference to pharmacovigilance.

Authors:  Philippe Mougenot; Olivier Lidove; Catherine Caillaud; Philippe Arnaud; Thomas Papo
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

4.  Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants.

Authors:  Silvia Lombardi; Mattia Ferrarese; Saverio Marchi; Paolo Pinton; Mirko Pinotti; Francesco Bernardi; Alessio Branchini
Journal:  RNA Biol       Date:  2019-10-15       Impact factor: 4.652

5.  Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.

Authors:  Jean-Michel Itier; Gwénaëlle Ret; Sandra Viale; Lindsay Sweet; Dinesh Bangari; Anne Caron; Françoise Le-Gall; Bernard Bénichou; John Leonard; Jean-François Deleuze; Cécile Orsini
Journal:  J Inherit Metab Dis       Date:  2014-05-22       Impact factor: 4.982

6.  Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry.

Authors:  Yung-Hsiu Lu; Po-Hsun Huang; Li-Yun Wang; Ting-Rong Hsu; Hsing-Yuan Li; Pi-Chang Lee; Yu-Ping Hsieh; Sheng-Che Hung; Yu-Chen Wang; Sheng-Kai Chang; Ya-Ting Lee; Ping-Hsun Ho; Hui-Chen Ho; Dau-Ming Niu
Journal:  J Hum Genet       Date:  2017-11-15       Impact factor: 3.172

7.  Depression in adults with Fabry disease: a common and under-diagnosed problem.

Authors:  A L Cole; P J Lee; D A Hughes; P B Deegan; S Waldek; R H Lachmann
Journal:  J Inherit Metab Dis       Date:  2007-11-12       Impact factor: 4.982

Review 8.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

9.  Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease.

Authors:  M Kobayashi; T Ohashi; M Sakuma; H Ida; Y Eto
Journal:  J Inherit Metab Dis       Date:  2008-01-21       Impact factor: 4.982

10.  Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

Authors:  Agnes B Fogo; Leif Bostad; Einar Svarstad; William J Cook; Solange Moll; Federic Barbey; Laurette Geldenhuys; Michael West; Dusan Ferluga; Bojan Vujkovac; Alexander J Howie; Aine Burns; Roy Reeve; Stephen Waldek; Laure-Hélène Noël; Jean-Pierre Grünfeld; Carmen Valbuena; João Paulo Oliveira; Justus Müller; Frank Breunig; Xiao Zhang; David G Warnock
Journal:  Nephrol Dial Transplant       Date:  2009-10-15       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.